



## Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 22, 2021

SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: [DARE](#)), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference being hosted by the Cantor Fitzgerald Healthcare team September 27 – 30, 2021.

Date: Thursday, September 30<sup>th</sup>  
Time: 12:40 p.m. ET  
Presenter: Sabrina Martucci Johnson, President and Chief Executive Officer  
Live webcast: <https://wsw.com/webcast/cantor12/dare/2054360>

An archived webcast of Ms. Johnson's presentation will be available following the event until October 15, 2021 under "Presentations, Events & Webcasts" in the Investors section of the company's website at <http://ir.darebioscience.com>.

### About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré's product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about Daré's full portfolio of women's health product candidates, and mission to deliver differentiated therapies for women, please visit [www.darebioscience.com](http://www.darebioscience.com).

Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (<http://ir.darebioscience.com>), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré's website mentioned above.

### Contacts:

Investors on behalf of Daré Bioscience, Inc.:  
Lisa Walters-Hoffert, Chief Financial Officer  
Daré Bioscience, Inc.  
[walters@ darebioscience.com](mailto:walters@ darebioscience.com)  
858.926.7655

OR

Media on behalf of Daré Bioscience, Inc.:  
Jake Robison  
Canale Communications  
[jake.robison@canalecomm.com](mailto:jake.robison@canalecomm.com)  
619.849.5383

Source: Daré Bioscience, Inc.



Source: Daré Bioscience, Inc.